Novartis’ Entresto shows benefits for HFrEF patients with diabetes

Novartis has announced new clinical trial data that demonstrates the benefits of its drug Entresto in the treatment of patients with reduced ejection fraction heart failure (HFrEF) and diabetes.

Data from a new post-hoc analysis of the PARADIGM-HF trial has shown how Entresto can help to improve glycaemic control HFrEF patients who also had diabetes, with the new use of insulin was reduced by 29 percent in these individuals.

This is a potentially important finding, as diabetes is a major risk factor in heart failure and has been strongly linked to faster progression of the disease, putting patients at an increased risk of hospitalisation and death.

A total of 3,778 HFrEF patients were enrolled in the PARADIGM-HF trial, making it the largest clinical trial ever conducted in the field of heart failure.

Vasant Narasimhan, global head of drug development and chief medical officer at Novartis, said: "We are excited about these results and committed to improving our understanding of the benefits of Entresto in different heart failure patient populations."

Entresto is designed to reduce the risk of cardiovascular death and hospitalisation in patients with chronic heart failure and reduced ejection fraction, though it is not indicated to treat diabetes.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.